

# Press release - 2010 revenues

Bezons, January 13th, 2011; 5:45 pm

# 2010 revenues up 20% to €20.7 million Order book of €17.3 million, 6.9 times higher than end of 2009

Bezons, January 13th, 2011 - 5:45 pm - RIBER, the global leader for molecular beam epitaxy (MBE), is announcing  $\notin 20.7$  million in full-year revenues, including  $\notin 13.1$  million for the fourth quarter. RIBER is able to confirm its forecast for earnings growth over the whole year in 2010.

At December 31st (€'000,000)	2010	2009	Change
Systems	11.1	10.1	+10%
Services and accessories	6.5	4.7	+38%
Cells and sources	3.1	2.5	+24%
Total reported revenues	20.7	17.3	+20%
Systems order book	13.3	1.0	x13.3
Services and accessories order book	1.8	1.3	+38%
Cells and sources order book	2.2	0.2	x11
Total order book	17.3	2.5	x6,9

MBE system sales are up 10% to €11.1 million. This growth reflects the good level of sales to research centers and the upturn in demand from industrial firms for compound semiconductors. 10 MBE machines were delivered in 2010, including two production systems.

In line with the objectives set, the services and accessories business has continued to develop at a strong rate, with revenues climbing to a record level of €6.5 million, representing growth of 38% in relation to 2009.

Sales of evaporation sources and cells increased by 24%, confirming the relevance of the strategy to diversify into the strong-growing markets for organic LEDs (OLED) and thin-layer solar panels (CIGS technology).

In 2010, the breakdown of RIBER's sales was as follows: Europe (56% of which 35% in Russia), Asia (28%) and North America (16%).

## Favorable outlook for 2011

RIBER has good visibility for 2011. The order book represents €17.3 million, 6.9 times higher than at December 31st, 2009. It includes 10 MBE systems, with three production systems and seven research systems. One of these systems is deliverable after 2011.

It is important to note that the order book does not include the major OLED effusion cell contract signed at the start of January 2011 for several million euros.

RIBER's commercial development illustrates the relevance of its strategy, based on:

- Continuing to further strengthen RIBER's leadership on the market for MBE research and production systems;
- Capitalizing on the installed base and growing sales of epitaxy equipment (effusion cells, etc.), spare parts and accessories, as well as the corresponding services;
- Releasing a range of high value-added equipment and services on the market for strong-growth application fields (thin-layer solar panels, OLED lighting and flat screens, etc.).

2010 full-year earnings will be released on March 24th, 2011 (after close of trading).

#### **About RIBER:**

Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. This high-technology equipment is essential for the manufacturing of compound semiconductor materials and new materials that are used in numerous consumer applications, such as new information technologies, OLED flat screens and new generation solar cells.

Riber is listed on Euronext Paris Compartment "C" and is part of the CAC IT index.

ISIN: FR0000075954 Reuters code: RIBE.PA Bloomberg code: RIB: FP

Riber has been innovation certified by OSEO, the dedicated French innovation agency, enabling it to qualify for French innovation mutual funds (FCPI).

### Your contacts:

RIBER CALYPTUS
Olivier Handschumacher Cyril Combe

tel: +33 1 39 96 65 00 tel: +33 1 53 65 68 68 ohandschumacher@riber.fr cyril.combe@calyptus.net

www.riber.com